Abstract
Abstract Objective: The purpose of this study was to verify the sensitizing and toxicity-alleviating effects of Astragalus-zedoary on oxaliplatin chemotherapy for colorectal cancer (CRC). Materials and Methods: MC38 tumor-bearing mice were randomly divided into three groups and treated with oxaliplatin or Astragalus-zedoary combined with oxaliplatin. The general physical status, changes in body weight, and tumor weight of the mice were recorded. Pathological morphology of the tumor was detected by hematoxylin and eosin staining, apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling, and epithelial–mesenchymal transition (EMT) and drug resistance-related factors were detected by immunohistochemistry, western blotting, and real-time polymerase chain reaction. Results: The experimental results showed that compared with oxaliplatin alone, mice in the combination group had higher body weight and mental state, shinier hair, reduced tumor weight, increased tumor inhibition and apoptosis rates, upregulated expression of E-cadherin protein and mRNA, and downregulated expression of N-cadherin, multidrug resistance-associated protein 1 (MRP1), and P-glycoprotein. It was confirmed that the combination of Astragalus-zedoary and oxaliplatin had a synergistic tumor inhibition effect, with a good ability to interfere with the EMT process of CRC tumor cells, inhibit the transporter, and increase the sensitivity of tumor cells to oxaliplatin. Conclusions: Astragalus-zedoary exhibits an enhanced antitumor effect and can play a synergistic role with oxaliplatin chemotherapy, thereby significantly enhancing the long-term survival rate and quality of life of tumor-bearing mice.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call